期刊文献+

氨基末端B型利钠肽在心功能分级中的应用 被引量:19

The Use of the Serum NT-proBNP Level in the Grading of Cardiac Function
在线阅读 下载PDF
导出
摘要 目的:研究氨基末端B型利钠肽(NT-proBNP)水平在心功能分级中的应用。方法:选取2007年11月-2008年4月,复旦大学附属中山医院心血管疾病患者204例(年龄12~90岁),健康人群(对照组)40例(年龄25~65岁)。按照纽约心脏病协会心功能分级(NYHA)将患者分为4组,其中NYHA Ⅰ级33例,NYHA Ⅱ级45例,NYHA Ⅲ级90例,NYHA Ⅳ级36例。测定患者血清NT-proBNP水平,同时进行超声心动图检查,记录患者左心射血分数(LVEF)。分析血清NT-proBNP水平与NYHA分级和LVEF的关系。结果:区分健康人群组和NYHA Ⅰ级疾病组NT-proBNP水平的截点值为136.8ng·L-1,敏感度和特异性分别为88.1%和90.9%;区分NYHA Ⅰ~Ⅱ级和NYHA Ⅲ~Ⅳ级疾病组NT-proBNP水平的截点值为768.8ng·L-1,敏感度和特异性分别为93.4%和87.2%。将对照组和疾病组分别按性别和年龄进行分组统计,结果显示各年龄组别区分健康人群组和NYHA分级疾病组NT-proBNP水平的截点值有所变化,65岁以上各组NT-proBNP水平的截点值显著高于65岁以下同组水平。疾病组LVEF值和血清NT-proBNP水平存在一定的相关性(r=0.699,P<0.01)。结论:血清NT-proBNP可用于NYHA分级。在不同年龄段使用相应的cut-off值,可提高NYHA分级的敏感度和特异性。联合使用NT-proBNP和LVEF值对于NYHA分级有一定的辅助诊断作用。 Objective:To study the use of NT-proBNP in the auxiliary diagnosis of cardiac functional grading. Methods: There were 204 patient(age from 12 to 94) with the cardiovascular diseases enrolled the Zhongshan hospital from the November of 2007 to the April of 2008. There are also 40 healthy people(age from 25 to 65) as the normal control group. These patient were divided into four groups according to the NYHA classification. There were 33 patient in NYHA Ⅰ,45 patient in NYHA Ⅱ,90 patient in NYHA Ⅲand 23 patient in NYHA Ⅳ. The level of the serum NT-proBNP in the five groups was detected by the Roche 2010 chemiluminescence immunoassay assay.The result of LVEF were recorded. The relationship among NT-proBNP,LVEF and NYHA were analyzed by SPSS11.0. Results: The result of ROC curve show that the concentration of NT-proBNP to classify healthy people and the patient with NYHA functional classification was 136.8 ng·L^-1, the sensitivity was 88.1% and the specificity was 90.9%, respectively, the concentration of NT-proBNP to classify NYHA Ⅰ-Ⅱ and NYHA Ⅲ-Ⅳwas 768.8 ng·L^-1, the sensitivity was 93.4% and specificity was 87.2%, respectively. Dividing the apparently healthy individual and the patient with age and sex, the result shows that the cut-off value between apparently healthy individual and NYHA functional classification was different.The cut-off value of NT-ProBNP in those aged ≥65 yearsis higher than those aged ≤65 years obviously. Binary varietic regression analysis showed that there were unvarying correlations between NT-proBNP concentrations and LVEF(r=0.699,P〈0.01). Conclusion: Serum NT-proBNP can be used in NYHA functional classification. We can use different cut-off according to the age, it can improve the sensitivity and specificity to NYHA functional classification. It has the effect of auxiliary diagnosis to combine NT-proBNP and LVEF in NYHA functional classification.
出处 《中国临床医学》 2009年第2期321-324,共4页 Chinese Journal of Clinical Medicine
关键词 氨基末端B型利钠肽 左心射血分数 纽约心脏病协会心功能分级 N-terminal pro-brainnatriureticpeptide Left ventricular ejection fraction NYHA classification grading of cardiac function
  • 相关文献

参考文献7

  • 1Criteria Committee New York Heart Association Inc. Diseases of the heart and blood vessels Nanenclature and critera for dignoses[M]. sixth edition. Boston: little Brown 1964:114.
  • 2Hunt SA,Baker DW, Chin MH,et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult : executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines(committee to revise the 1995 guidelines for the evalution and management of heart failure) :developed in collaboration with the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America[J]. Circulation,2001,104(24) : 2996-3007.
  • 3Pemberton CJ ,Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload[J]. Hypertension, 2000,36 : 355-335.
  • 4Williams SG, Ng LL, O'Brien RJ, et al. Complementary roles of simple variables, NYHA and N-BNP, in indicating aerobie capacity and severity of heart failure[J]. Int J Cardiol, 2005,102 (2):279 -286.
  • 5Hunt SA, Abrabam WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis an d management of chronic heart failure in the adult[J].Circulation, 2005, 112 : 154-235.
  • 6洪斌,金雪娟,罗勇,周兰珠,蔡前芳,葛均波.动态脑钠肽水平改变对充血性心力衰竭患者近期预后的预测价值[J].中国临床医学,2009,16(1):25-27. 被引量:3
  • 7潘柏申,蔡乃绳,李清,范维琥,李勇,郭玮,周琰,陶青.表面健康人群氨基末端B型利钠肽参考范围调查[J].中华检验医学杂志,2006,29(1):23-26. 被引量:66

二级参考文献21

  • 1Bozkurt B,Mann DL. Use of biomarkers in the management of heart failure. Are we there yet? Circulation ,2003,107 : 1231-1233.
  • 2White HD,French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol,2003,42 : 1917-1920.
  • 3Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Euro Heart J,2001,22 : 1527-1560.
  • 4Hunt SA,Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation ,2005,112 :e154-e235.
  • 5de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet ,2003,362:316-322.
  • 6Yeo KTJ, Wu AHB, Apple FS, et al. Muhicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta,2003,338 : 107-115.
  • 7Vasan RS. Expanding indications for natriuretic peptides:impottance of better new (research) protocols. Am Heart J ,2004,148:743-746.
  • 8Panteghini M,Pagani F,Yeo KTJ,et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem,2004,50:327-332.
  • 9Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation ,2004,110 : 104-106.
  • 10Redfield MM, Rodeheffer R J, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration : impact of age and gender. J Am Coll Cardiol,2002 ,40 :976-982.

共引文献67

同被引文献154

引证文献19

二级引证文献168

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部